AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Clinuvel Pharmaceuticals is an ASX-listed global specialty pharmaceutical company
- In 1HFY24, CUV’s revenue jumped 9.9% YoY to AUD 32.26 million
- Wolgen (Philippe Jacques) has maximum stake in the company with a shareholding of nearly 6.83%
Clinuvel Pharmaceuticals Limited (ASX:CUV) is an international specialty pharmaceutical firm, listed on ASX. Its focus lies in commercializing and advancing treatments for individuals afflicted with genetic, metabolic, systemic, and life-threatening acute conditions. Additionally, the company provides healthcare solutions to the broader public.
In the first half of the financial year 2024 (1HFY24), the company recorded 9.9% YoY rise in revenues to AUD 32.26 million, 1.4% YoY increase in net profit before tax to AUD 14.81 million and 11.2% YoY growth in cash and term deposits to AUD 174.45 million.
During the reported period, the company generated revenues from sales of SCENESSE. The sales were backed by a rise in patients receiving treatments in North America for the first time.
Top 10 shareholders of CUV
The top 10 shareholders of CUV have around 23.72% shareholding in the company. Wolgen (Philippe Jacques) and Ender 1, L.L.C., have the maximum stake in the firm with a shareholding of around 6.83% and 5.17%, respectively.
Recent business update
On 20 March 2024, the company released a newsletter which highlighted the new developments in photodermatology and mentioned several times that SCENESSE is a breakthrough drug in erythropoietic protoporphyria and vitiligo. The primary aim of the year will be advancing the commercial foothold in Europe and the US and progressing development of melanocortin drug candidates.
On 14 March 2024, the company notified that it would undertake a 12 month on-market share buy-back program of up to 1.5 million shares. The repurchase would depend upon share price, capital position of the company and market performance.
Share performance of CUV
CUV shares closed 0.73% lower at AUD 13.67 apiece on 20 March 2024. With this, CUV’s share price declined by 30.40% in the last one year and had decreased by almost 17.84% in the last one month.
The 52-week high of CUV is AUD 21.53, recorded on 2 May 2024, while the 52-week low is AUD 12.96, recorded on 11 March 2024.
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 20 March 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
